Eplerenone cuts risk of death in heart failure

摘要

Compared with placebo, aldosterone antagonist eplerenone reduces the risk of death and admission to hospital among patients with systolic heart failure and mild symptoms, a study has shown. The Pfizer-funded trial aimed to find out whether eplerenone had an effect on the clinical outcomes of those with systolic heart failure and mild symptoms when added to evidence-based therapy. Over 2,700 patients were randomised to receive either eplerenone or placebo for the planned four-year trial. P573